Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD.

Clin Cancer Res. 2017 Apr 1;23(7):1862-1874. doi: 10.1158/1078-0432.CCR-16-0620. Epub 2016 Sep 23.

2.

Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells.

Liu Y, Qiang W, Xu X, Dong R, Karst AM, Liu Z, Kong B, Drapkin RI, Wei JJ.

Oncotarget. 2015 Nov 17;6(36):38983-98. doi: 10.18632/oncotarget.5493.

3.

Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.

Novak M, Lester J, Karst AM, Parkash V, Hirsch MS, Crum CP, Karlan BY, Drapkin R.

Gynecol Oncol. 2015 Oct;139(1):104-11. doi: 10.1016/j.ygyno.2015.07.100. Epub 2015 Jul 20.

4.

In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.

Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch M, Vazquez F, Root DE, Beroukhim R, Drapkin R, Hahn WC.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1102-7. doi: 10.1073/pnas.1311909111. Epub 2014 Jan 2.

5.

Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, Etemadmoghadam D, Bowtell DD, Drapkin R.

Cancer Res. 2014 Feb 15;74(4):1141-52. doi: 10.1158/0008-5472.CAN-13-2247. Epub 2013 Dec 23.

6.

Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R.

Cancer Cell. 2013 Dec 9;24(6):751-65. doi: 10.1016/j.ccr.2013.10.013.

7.

Primary culture and immortalization of human fallopian tube secretory epithelial cells.

Karst AM, Drapkin R.

Nat Protoc. 2012 Sep;7(9):1755-64. doi: 10.1038/nprot.2012.097. Epub 2012 Aug 30.

PMID:
22936217
8.

Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4.

Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, Fogal V, Ruoslahti E, Hahn WC, Bhatia SN.

Sci Transl Med. 2012 Aug 15;4(147):147ra112. doi: 10.1126/scitranslmed.3003778.

9.

The new face of ovarian cancer modeling: better prospects for detection and treatment.

Karst AM, Drapkin R.

F1000 Med Rep. 2011;3:22. doi: 10.3410/M3-22. Epub 2011 Nov 1.

10.

Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.

Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, Hecht JL, Drapkin R.

Gynecol Oncol. 2011 Oct;123(1):5-12. doi: 10.1016/j.ygyno.2011.05.021. Epub 2011 Jun 17.

11.

Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.

Karst AM, Levanon K, Drapkin R.

Proc Natl Acad Sci U S A. 2011 May 3;108(18):7547-52. doi: 10.1073/pnas.1017300108. Epub 2011 Apr 18.

12.

Ovarian cancer pathogenesis: a model in evolution.

Karst AM, Drapkin R.

J Oncol. 2010;2010:932371. doi: 10.1155/2010/932371. Epub 2009 Sep 6.

13.

Nuclear factor kappa B subunit p50 promotes melanoma angiogenesis by upregulating interleukin-6 expression.

Karst AM, Gao K, Nelson CC, Li G.

Int J Cancer. 2009 Jan 15;124(2):494-501. doi: 10.1002/ijc.23973.

14.

BH3-only proteins in tumorigenesis and malignant melanoma.

Karst AM, Li G.

Cell Mol Life Sci. 2007 Feb;64(3):318-30. Review.

PMID:
17192811
15.
16.

PUMA expression is significantly reduced in human cutaneous melanomas.

Karst AM, Dai DL, Martinka M, Li G.

Oncogene. 2005 Feb 3;24(6):1111-6.

PMID:
15690057

Supplemental Content

Loading ...
Support Center